Royalty Pharma plc (RPRX)

Royalty Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	11,701	16,782	23,997	24,196	30,386	-
Market Cap Growth	-17.07%	-30.07%	-0.82%	-20.37%	-	-
Enterprise Value	16,308	21,683	28,686	28,489	33,553	5,445
PE Ratio	14.62	14.79	560.27	39.04	31.16	-
PS Ratio	5.23	7.13	10.73	10.57	14.32	-
PB Ratio	1.19	1.66	2.52	2.36	3.07	-
P/FCF Ratio	4.47	5.64	11.19	12.10	14.93	-
P/OCF Ratio	4.47	5.62	11.19	11.99	14.93	-
EV/Sales Ratio	7.28	9.21	12.82	12.44	15.81	3.00
EV/EBITDA Ratio	16.58	16.40	124.29	36.25	29.64	2.08
EV/EBIT Ratio	16.58	16.40	124.29	36.25	29.64	2.08
EV/FCF Ratio	6.23	7.29	13.38	14.25	16.49	3.84
Debt / Equity Ratio	0.62	0.61	0.75	0.69	0.59	1.02
Debt / EBITDA Ratio	6.24	4.64	30.83	9.03	5.14	2.38
Debt / FCF Ratio	2.34	2.06	3.32	3.55	2.86	4.40
Quick Ratio	12.48	7.78	2.11	16.77	8.73	2.50
Current Ratio	12.52	7.90	2.19	16.81	8.76	2.50
Asset Turnover	0.14	0.14	0.13	0.14	0.14	0.15
Interest Coverage	5.33	7.06	1.23	4.73	7.21	9.74
Return on Equity (ROE)	8.10%	11.50%	0.40%	6.10%	16.50%	44.30%
Return on Assets (ROA)	4.90%	6.80%	0.20%	3.70%	6.40%	19.70%
Return on Capital (ROIC)	5.87%	9.20%	1.85%	8.25%	10.15%	21.25%
Earnings Yield	6.83%	6.76%	0.18%	2.56%	3.21%	-
FCF Yield	22.38%	17.73%	8.93%	8.26%	6.70%	-
Dividend Yield	3.25%	2.80%	1.90%	1.70%	0.60%	-
Payout Ratio	47.46%	31.50%	760.00%	45.60%	22.70%	-
Buyback Yield / Dilution	1.61%	-37.66%	-5.59%	-10.48%	36.94%	-
Total Shareholder Return	4.86%	-34.86%	-3.69%	-8.78%	37.54%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).